4

MOL #30015 Introduction
Natural products have become more and more important in drug discovery for the treatment of human diseases, such as cancer (Newman et al., 2003) . However, mechanisms of action of most of the natural medicinal products are unclear. Withania somnifera Dunal (ashwagandha, also named "Indian Winter Cherry" or "Indian Ginseng", belonged to Solanaceae family) has been used for over centuries in Ayurvedic medicine, the traditional medical system in India as a remedy for a variety of musculoskeletal conditions and as a tonic to improve the overall health (Mishra et al., 2000) . Its root extract has also been accepted as a dietary supplement in the United
States recently (Jayaprakasam et al., 2003) . Many reports suggest its broad medical application with anti-inflammation, anti-tumor, cardiopretection, neuroprotection, and immunomodulation properties (Agarwal et al., 1999; Ahmad et al., 2005; Devi et al., 1992; Gupta et al., 2004; Owais et al., 2005; Rasool and Varalakshmi, 2006) . So far over 35 chemical constituents including alkaloids and withanolides have been isolated from this plant, in which Withaferin A (WA), a steroidal lactone, is the most important of the withanolides (Mishra et al., 2000) . Several properties of WA have been reported, anti-tumor effect, radiosensitizing activity Devi et al., 2000; Devi et al., 1995; Sharada et al., 1996; Devi and Kamath, 2003) , antiangiogenesis through NF-κB inhibition (Mohan et al., 2004; Yokota et al., 2006) , cytoskeletal architecture alteration by covalently binding annexin II (Falsey et al., 2006) , and apoptosis induction through PKC pathway in leishmanial cells (Sen et al., 2006) .
The proteasome, a highly selective proteinase complex, is viewed as a possible target for the therapy of cancer (Goldberg, 1995; Dou and Li, 1999) . It is composed of two complex components, the cylindric 20S core particle and two 19S cap particles which dock onto both ends This article has not been copyedited and formatted. The final version may differ from this version. 
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of the 20S proteasome (Goldberg, 1995; Dou and Li, 1999) . The barrel-shaped 20S unit consists of 2 rings of 7 α subunits and 2 rings of 7 β subunits, stacked in the order α β β α . The β 5, β 2 and β 1 subunits are responsible for three different catalytic activities of the proteasome, chymotrypsin-like, trypsin-like and peptidyl glutamyl peptide hydrolyzing, respectively (Goldberg, 1995; Dou and Li, 1999) . In all the three β -subunits, the amino terminal threonine (NThr) is the catalytically active amino acid. Many endogenous proteins including cyclins, transcription factors and tumor suppressors are degraded by the proteasome (Glotzer et al., 1991; Pagano et al., 1995; Chen et al., 1996) . These proteins are marked by ubiquitins for degradation and recognized by the 19S particle of the proteasome (Nandi et al., 2006) .
Previously, we reported that some dietary flavonoids containing aromatic ketone structure were able to inhibit the proteasomal chymotrypsin-like activity (Chen et al., 2005) . We proposed that the aromatic ketone carbon would interact with the hydroxyl group of the N-threonine of the proteasomal β5 subunit, forming a covalent bond and causing inhibition of the proteasomal chymotrypsin-like activity (Chen et al., 2005) .
By chemical structure analysis, we noticed that WA contains two conjugated ketone bonds ( Fig. 1A ) and therefore hypothesized that WA might be a proteasome inhibitor. In the current study, we report that the nucleophilic susceptibility and in silico docking studies predict that C 1 and C 24 of WA are highly susceptible towards a nucleophilic attack by the hydroxyl group of Nterminal threonine of the proteasomal chymotrypsin subunit β5. WA inhibits the chymotrypsinlike activity of a purified 20S proteasome and 26S proteasome in cultured prostate cancer cells and tumors. Inhibition of prostate tumor cellular proteasome in vitro and in vivo by WA was accompanied with the accumulation of the proteasome target proteins Bax, IκB-α and p27
Kip1
This article has not been copyedited and formatted. The final version may differ from this version. Whole cell extract preparation and Western blotting analysis. A whole cell extract was prepared as described previously (An and Dou, 1996) . Western blotting assay using Enhanced
Chemiluminescence Reagent was performed as described previously (Li and Dou, 2000) .
Nuclear protein extraction. The whole cell pellet was suspended with cell lysis buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 2 µg/ml aprotinin, 2 µg/ml leupeptin, 0.5 mg/ml benzamidine) and incubated on ice, followed by centrifuge. Nuclear pellet was resuspended in nuclear extraction buffer (20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 5 mM PMSF, 2 µg/ml aprotinin, 2 µg/ml leupeptin, 0.5 mg/ml benzamidine), followed by incubation on ice for 30 min. After centrifuge, nuclear proteins were extracted from the supernatant.
Nucleophilic susceptibility analysis. Analysis of electron density surface colored by nucleophilic susceptibility was generated using Quantum CAChe (Fujitsu; Fairfield, NJ). Highly susceptible atoms for nucleophilic attack were showed by two-colored "bull's-eyes".
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In silico docking study. WA was docked to the 20S proteasome as described previously (Kazi et al., 2003; Smith et al., 2004 Inhibition of the cellular proteasome activity by WA. PC-3 or LNCaP cells were treated as described in Figure Legends . Chymotrypsin-like activity was measured in the prepared whole cell extracts (7.5 µ g per sample) as described above. To detect proteasome inhibition by WA in intact cells, 40 µmol/L of Suc-LLVY-AMC substrate was incubated in 100 µ l treated or untreated cells (5000-8000 in 96-well plate) for 2 hours, followed by measurement of chymotrypsin-like activity.
Caspase-3 (or -7) activity assay. PC-3 or LNCaP cells were treated with different concentrations of WA, reduced WA, Celastrol or Dihydrocelasrtol for indicated hours. The prepared whole cell extracts (30 µ g per sample) were then incubated with 40 µmol/L of the caspase-3/-7 substrate Ac-DEVD-AMC in 100 µ l assay buffer at 37°C for at least 2 hours. The release of the AMC groups was measured as described above.
This article has not been copyedited and formatted. The final version may differ from this version. Body weight was measured every other day.
Proteasome inhibition and apoptosis assays using tumor tissue samples. The proteasome or caspase activity assays and Western blotting using animal tumor tissue samples were performed similarly as described above using cultured prostate cancer cells. TUNEL assay, p27 kip1 and CD31 immunostaining, and Hematoxylin and Eosin (H & E) staining in tumor tissues were performed following manufactory protocols .
Statistical analysis.
One-way ANOVA was used to evaluate differences between treated and control nude mice with respect to tumor growth, followed by Welch two sample t-test to determine the differences between each two groups. P<0.05 was considered statistically significant.
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Results
Computational electron density and docking studies suggest that C 1 and C 24 in WA could interact with the proteasomal β5 subunit and inhibit the chymotrypsin-like activity. By chemical analysis, we found that WA, isolated from Indian Winter Cherry, has a conjugated ketone structure ( Fig 1A) that might be responsible for interaction with the hydroxyl (OH) group of the N-threonine (N-Thr) of the β5 subunit, forming a covalent bond and causing inhibition of the proteasomal chymotrypsin-like activity (Chen et al., 2005; Yang et al., 2006) . To test this idea, we first performed computational electron density analysis for the WA molecule. The result ( Fig. 1B ) predicts that WA is highly susceptible towards a nucleophilic attack at C 1 in Aring and C 24 in E-ring, denoted by "bull's eyes" with white or red center respectively (Fig. 1B) .
We then performed an in silico docking study to aid in the understanding of possible binding and inhibition of WA. Results from computational modeling indicate that WA binds the chymotrypsin site in an orientation and conformation that is suitable for a nucleophilic attack by the OH group of N-Thr of β5 subunit. There were only two major docking modes obtained. One with the lowest docked free energy (-9.93 kcal/mol) was repeated for 42 out of 100 runs (42% probability), showing that the distance from the electrophilic C 24 of WA to the OH of β5 N-Thr was 3.19 Å (Fig. 1C ). Another docking mode (26% probability; -9.30 kcal/mol) showed 2.70 Å between C 1 and the OH of β5 N-Thr (Fig. 1D ). Since nucleophilic attack could occur within 4 Å (Smith et al., 2004) , C 24 and C 1 in WA could interact with the proteasomal β5 and inhibit the chymotrypsin-like activity. 
WA potently inhibits
MOL #30015
direct evidence for the inhibition of proteasomal chymotrypsin-like activity by WA, we performed a cell-free proteasome activity assay using a purified rabbit 20S proteasome in the presence of WA at up to 50 µmol/L. The chymotrysin-like activity of the purified 20S proteasome was significantly inhibited by WA with an IC 50 value of 4.5 µmol/L (Fig. 1E ).
In order to determine in vivo effects of proteasome inhibition by WA, androgen-independent PC-3 prostate cancer cells were treated with WA at 5, 10 or 20 µmol/L for 4 or 16 hours (dosedependent) or 10 µmol/L WA for up to 24 hours (kinetics), followed by measuring proteasome inhibition by the cellular proteasomal activity assay. The proteasomal chymotrypsin-like activity was inhibited by WA in both dose-and time-dependent manners ( Fig. 2A, B) . Compared to its potency to a purified 20S proteasome (IC 50 4.5 µmol/L ; Fig. 1E ), WA reached 30-50% inhibition of the cellular proteasomal chymotrypsin-like activity at 10 to 20 µmol/L (see Discussion). The kinetic study also showed proteasome inhibition occurred at as early as 2 hours after addition of WA and increased gradually after 24 hours (Fig. 2B) . Accompanying with proteasome inhibition, ubiquitinated proteins was also accumulated in dose-and time-dependent manners ( Fig. 2C, D) . Consistent with kinetic proteasome inhibition, accumulation of ubiquitinated proteins was started as early as 2 hours and increased to the highest after 24 hours (Fig. 2D) . Furthermore, we observed levels of Bax and IκB-α, two well-known target proteins of the proteasome (Li and Dou, 2000; Chen et al., 1996) , increased from 2 hours and peaked at about 8-12 hours and 4-8 hours, respectively (Fig. 3D) . Accumulation of another proteasome target protein p27 was peaked at 12 hours (Fig. 2D) . These results confirm that WA inhibits cellular proteasome activity in PC-3 cells.
It has been shown that WA suppresses angiogenesis through NF-κB inhibition (Mohan et al., 2004 ) and that proteasome is required by nuclear translocation of p65/NF-κB and therefore activation of NF-κB (Palombella et al., 1994; Panwalkar et al., 2004) . We then examined whether WA-induced proteasome inhibition leads to NF-κB inactivation by detecting levels of nuclear p65/NF-κB in the same kinetic study. Fig. 2E showed that inhibition of NF-κB nuclear translocation by WA is time-dependent, from 13% at 2 hours to ~50% at 24 hours. Nuclear actin protein was used to normalize p65/NF-κB levels.
Induction of apoptosis by WA in androgen-independent PC-3 prostate cancer cells. It has been shown that inhibition of the tumor cellular proteasome activity is associated with apoptosis induction (An et al., 1998; Lopes et al., 1997) . To determine whether WA could induce apoptotic death in PC-3 cells along with proteasome inhibition and NF-κB inactivation, in the same experiment we measured apoptotic cell death by caspase-3 activation, PARP cleavage, and cellular apoptotic morphological changes in the aliquots of PC-3 cells treated with WA. Figure   3A shows that WA induces caspase-3 activation in dose-dependent manner: from 2-fold increase by 5 µmol/L of WA to 4-fold increase by 20 µmol/L of WA after 16 hours (Fig. 3A) . The cleaved PARP fragment p85/PARP was also detected after treatment of 10-20 µmol/L WA for 24 hours (Fig. 3B) , supporting the activation of caspase-3 by WA. If apoptosis were induced through proteasome inhibition, we would expect that proteasome inhibition should occur before apoptosis. Indeed, in the same kinetic experiment, caspase-3 activation was not detected until after 24 hours (Fig. 3C ) and PARP cleavage was also detected at 24 hours (Fig. 3D ), while proteasome inhibition was observed at as early as 2 hours (Fig. 2B, C) . The morphological changes induced by WA were also consistent with the molecular events, showing that 10 µmol/L This article has not been copyedited and formatted. The final version may differ from this version. 
of WA is enough to induce apoptotic features (round-up and condensation) and treated cells at this concentration started to shrink at 8 hours and became round-up at 24 hours (Fig. 3E ).
Effects of WA on androgen-dependent, AR-positive LNCaP prostate cancer cells. AR plays a critical role in the development of prostate cancer (Jenster, 1999) . It has been shown that proteasome inhibitors can reduce levels of AR protein although the involved molecular mechanisms are unknown (Lin et al., 2002) . If WA can inhibit proteasome activity, it should be able to suppress AR expression. To test this possibility, LNCaP cells were treated with different concentrations of WA for 3 or 6 hours. We found that ~30% and 50% of proteasomal chymotrypsin-like activity was inhibited by WA at 5 and 10 µmol/L, respectively ( Fig. 4A ) and that polyubiquitinated proteins were accumulated by WA at 5 µmol/L and further increased at 10 µmol/L (Fig. 4B) . Correspondingly, AR protein expression was decreased in a WA dosedependent manner (Fig. 4B) . Also, suppression of AR expression is associated with induction of apoptosis. Along with decreased AR protein levels by 5-10 µmol/L of WA, caspase-3 activity increased by 2.5-fold and PARP was cleaved by 10 µmol/L of WA (Fig. 4B, C) . Consistently, levels of apoptotic cells with condensed nucleus were increased after treatment with WA at 10 µmol/L (data not shown, but see Fig. 5D ).
To determine the kinetics of proteasome inhibition, AR suppression and apoptosis induction, LNCaP cells were treated with 10 µmol/L WA for different length of times. First we found that proteasomal activity was inhibited by 40% at 2 hours and by 70% after 24 hours treatment ( 
decreased by WA at 2 hours and became almost undetectable after 8 hours (Fig. 5B) . Following proteasome inhibition and AR suppression, PARP cleavage and caspase-3 activation were detected at 8 hours after treatment and further increased at 16 hours (Fig. 5B, C) . Compared to the proteasome inhibition and AR suppression at 2 hours, apoptosis was delayed for at least 6 hours. Morphologically, apoptotic features were found after 8 hours treatment (Fig. 5D) .
Interestingly, at 24 hours, p65/PARP was the main cleaved product detected (Fig. 5B) , which is mediated by activation of calpain (Tagliarino et al., 2003) . At this time point, caspase activity was decreased, associated with loss of p85/PARP (Fig. 5B-C) . 
proteasomal chymotrypsin-like activity. Consistently, accumulation of ubiquitinated proteins and Bax, IκB-α and p27, the three proteasome targets, were observed in the tissue extracts of WAtreated vs. control tumors (Fig. 6C) . Thus, proteasome inhibition in vivo by WA was demonstrated by multiple assays. Furthermore, increased caspase-3 activity was found in the tumor extract of WA-treated mouse, compared to the control (data not shown, and see below Fig.   7 ), suggesting that apoptosis in PC-3 tumors has been activated by WA treatment.
We next performed immunostaining assays using tumor tissues to further investigate the in situ proteasome inhibition and apoptosis by WA. Compared to vehicle control, increased expression of p27 protein was observed in the tumor tissues from WA-treated mice (Fig. 7A ), confirming proteasome inhibition in vivo by WA. In addition, apoptotic cells indicated by TUNEL positivity were observed in tumors from animals treated with WA (Fig. 7B) . The apoptosis-inducing ability of WA in tumors was further demonstrated by another apoptotic feature, condensed nucleus, detected in WA-treated tumors by Hematoxylin and Eosin staining (Fig. 7C) . It has been shown that WA is an angiogenesis inhibitor (Mohan et al., 2004; Yokota et al., 2006) . Consistently, we found that the expression of the endothelial marker CD31 in tumors was significantly inhibited by WA treatment (Fig. 7D) . Finally, as mentioned, one WA-treated tumor (at 4.0 mg/kg) became undetectable on day 7, and remained tumor-free to the end of the experiment. The tissues from the tumor location of this mouse were collected and analyzed by anatomy and H & E staining. The results show the presence of normal muscles without any tumorous characteristics (Fig. 7E) . Taken together, these data demonstrate that WA targets tumor proteasome, resulting in apoptosis induction and angiogenesis inhibition that are responsible for its observed antitumor effect.
The conjugated ketone structure of WA is required for its proteasome-inhibitory activity. To provide direct evidence for supporting our hypothesis that the conjugated ketone carbons are required for the proteasome inhibition, we tried to generate the reduced form of WA by reduction reaction since it is not commercial available. TLC analysis of the production after reduction reaction is consistent with formation of a reduced form of WA since (i) the new product has different mobility from that of WA and (ii) the new product has increased polarity (data not shown).
We first measured the effect of the reduced WA on the chymotrypsin-like activity of purified rabbit 20S proteasome using WA as a positive control. WA at 10 µmol/L caused proteasome inhibition by 90% while the reduced WA 10 µmol/L caused only by 30% (Fig. 8A ). Even at 25 µmol/L, the reduced WA did not inhibit more than 35% of the proteasomal activity (data not shown). These data suggested that reduction of WA have caused 3-fold decrease in its proteasome-inhibitory activity (Fig. 8A) . We then examined whether WA in reduced form is less active to inhibit cellular proteasome activity. LNCaP cells were treated with 10 µmol/L WA or reduced WA for up to 16 hours, followed by the proteasomal chymotrypsin-like activity assay.
WA inhibited the cellular proteasome by 40% after 2 hours treatment while reduced WA only caused 20% proteasome inhibition (Fig. 8B) . After 16 hours treatment, WA-mediated proteasome inhibition increased to ~60% while reduced WA retained 20% inhibition (Fig. 8B) .
Furthermore, WA caused dramatic decrease of AR protein expression at 2 hours, similar to what we observed previously (Figs. 8C vs . 5B). In sharp contrast, the reduced WA had little effect after even 16 hours treatment (Fig. 8C ).
To investigate whether the decreased proteasome-inhibitory and AR-suppressing activities of reduced WA is associated with decreased apoptosis induction, LNCaP cells treated with WA or reduced WA in the same experiment were analyzed for apoptosis. We found that WA, but not the reduced WA, caused a time-dependent caspae-3 activation and PARP cleavage (Fig. 8C, D) .
The conjugated ketone structure of WA is very similar to that present in Celastrol (Figs. 1A vs. 9A). Since the reduced form of Celastrol, Dihydrocelastrol (Fig. 9B) , is commercially available, we then used the pair of Celastrol and Dihydrocelastrol to further investigate the requirement of the conjugated ketone carbons for proteasome inhibition. As we reported previously, Celastrol inhibited the chymotrypsin-like activity of the purified 20S proteasome with an IC 50 2.5 µmol/L ( Fig. 9C ; Yang et al., 2006) . In comparison, the IC 50 value of Dihydrocelastrol to the purified proteasome was determined to be 10 µmol/L (Fig. 9C) , suggesting that reduction of the ketone in Celastrol caused 4-fold decrease in its proteasome-inhibitory activity. Similarly, treatment of LNCaP cells with 5 µmol/L of Celastrol for 16 hours results in greater proteasome inhibition than with Dihydrocelastrol under the same conditions (48% vs 4%; Fig. 9D ). In the kinetic experiment, Celastrol, but not Dihydrocelastrol, caused significant reduction of AR protein expression (Fig. 9E) . Finally, Celastrol has greater apoptosis-inducing ability than Dihydrocelastrol, as shown by caspase activation (Fig. 9F ) and PARP cleavage (Fig. 9E ) at both earlier time points and higher levels. Thus the comparison of highly oxidized WA or Celastrol at ketone structure to their reduced forms support that the conjugated ketone structure is critical for proteasome inhibition and apoptosis induction.
Discussion
WA is a natural product isolated from Withania somnifera Dunal (Solanaceae family) that has been used in traditional Indian medicine system (Mishra et al., 2000) . It has been shown that WA exerts anti-tumor properties (Devi et al., 1995; Sharada et al., 1996) . However, the involved direct molecular target has never been identified. Here we report that the proteasomal chymotrypsin subunit (β5) By analysis of the chemical structure (Fig. 1A) , we proposed that the conjugated ketone carbon of WA should be able to inhibit the proteasomal activity (Chen et al., 2005; Yang et al., 2006) .
The results of computational modeling further predicted that both C 1 and C 24 should be critical for this proteasome-inhibitory function. i) These two carbons show high susceptibility towards nucleophilic attack (Fig. 1B) ; ii) both of them can be placed into S 1 pocket (data not shown), the active site of β5 subunit of the proteasome; iii) the distances from these two carbons to the β5 Nterminal threonine are within the range for them to interact with the N-terminal theronine, the catalytically active amino acid of β5 subunit (Fig. 1C, D) ; iv) the lowest docking free energies of the two major docking modes (Fig. 1C, D) support the existence of the WA-proteasome complexes.
Consistent with the results from the nucleophilic susceptibility and in silico docking studies, WA directly and potently inhibited the chymotrypsin-like activity of the purified 20S proteasome with an IC 50 value of 4.5 µmol/L (Fig. 1E) . These results also further support that conjugated 20
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ketone carbon contributed to the proteasome-inhibitory potency (Chen et al., 2005) . It has been suggested that a double bond at position C 2-3 of WA was responsible for the cytotoxicity (Fuska et al., 1984) . Since removal of the C 2-3 double bond would affect the electron density of C 1 , our results are consistent with this previous study. The same report also suggested that dissociation of the double bond at C 24-25 did not caused any significant biological effects (Fuska et al., 1984) .
Whether such a change would affect the proteasome-inhibitory activity of WA needs to be determined.
To provide direct evidence for the requirement of the conjugate ketone structure for the proteasome inhibition and the subsequent apoptosis induction, we prepared the reduced form of
WA by reduction reaction and tested its effects using WA as a comparison. The obtained results of the proteasome activity assay in vitro and in cells demonstrated that reduction at the ketone structure of WA caused decreased proteasome-inhibitory activity (Fig. 8A-B) , leading to failure of AR suppression and apoptosis induction, as shown by lack of caspase-3 activation and PARP cleavage (Fig. 8C, D) . The known natural proteasome inhibitor Celastrol has an identical ketone structure to that of WA (Figs. 9A vs 1A) . We then tested the effect of the reduced analogue of Celastrol, Dihydrocelastrol. The IC 50 of Dihydrocelastrol to the purified proteasome was decreased by 4-fold, compared to Celastrol (Fig. 9C) . Deihydrocelstrol also has decreased potency to inhibit the cellular proteasome activity, decrease AR expression and induce apoptosis ( Fig. 9C-F) , further confirming that the conjugated ketone structure is critical for the proteasome-inhibitory and apoptosis-inducing function.
Comparing to inhibition of the purified proteasome inhibition (IC 50 4.5 µmol/L), we found that more WA (10-20 µmol/L) is needed to reach 50% proteasomal inhibition in prostate cancer cells proteasomal substrates Bax, IκB-α and p27 as well as ubiquitinated proteins (Fig. 2C) . In androgen-dependent LNCaP cells, we observed that WA induced AR suppression in accompany with the inhibition of proteasomal chymotrypsin-like activity (Figs. 4, 5) . Our finding was consistent with previous reports (Ikezoe et al., 2004; Lin et al., 2002; Pajonk et al., 2005) . A well-known proteasome inhibitor MG132 has been shown to block the transactivation of AR (Lin et al., 2002) . Whether WA down-regulates AR expression on the level of activity, protein or mRNA needs to be further investigated. Taken together, these data suggest that WA potently inhibits the proteasome activity and inhibits AR protein expression in cultured prostate cancer cells.
Since proteasome inhibition by WA caused accumulation of apoptosis-related proteins, Bax, p27 and IκB-α, we then investigated whether WA-induced proteasome inhibition triggers further apoptosis in the cultured prostate cancer cells. Indeed we found that the proteasome inhibition by WA was associated with apoptosis induction, as shown by caspase-3 activation, PARP cleavage and morphological changes (condensed nucleus) in both dose-and time-dependent manners (Figs. 3-5 ). More importantly, we noticed that the proteasomal inhibition occurred much earlier than apoptosis. The proteasomal inhibition was observed at as early as 2 hours after treatment with WA while caspase-3 activation and cleaved PARP were detected after 16 to 24 hours treatment in androgen-independent PC-3 cancer cells (Fig. 3) . In androgen-dependent cell line
LNCaP cells, we observed WA induced apoptosis with 6 hours delay after proteasome inhibition This article has not been copyedited and formatted. The final version may differ from this version. 
and AR suppression (Fig. 5) . Morphologically, WA-induced apoptotic features, round-up and condensed nucleus, were also detected after proteasome inhibition (Figs. 2-5 ). Taken together, these results demonstrate that proteasomal inhibition by WA triggers tumor cell apoptosis.
Next we determined whether the proteasome is an in vivo target of WA in PC-3 xenografts.
We found the inhibition of proteasomal chymotrypsin-like activity by 28-56% and accumulation of its substrates IκB-α, Bax and p27 as well as ubiquitinated proteins in WA-treated tumors compared to vehicle-treated tumors (Fig. 6B, C) . The proteasome inhibition was also visualized by the extensive accumulation of p27 in situ in WA-treated tumor tissues (Fig. 7A) . The same WA-treated tumor samples also showed TUNEL positivity and apoptotic morphological features, demonstrating that proteasome inhibition in vivo by WA also triggers apoptosis (Fig. 7) . Finally, WA at 4.0-8.0 mg/kg daily treatment caused 54-70% of tumor growth inhibition (Fig. 6A ) and complete tumor growth regression was found in one WA-treated tumor (Fig. 7E ). All these results suggest that WA can reach a therapeutic concentration in vivo that can directly target and inhibit the tumor cellular proteasome, resulting in apoptosis induction, angiogenesis suppression and tumor growth inhibition.
Natural medicines have been used for many years for cancer treatment although the mechanisms of action of most of them remain unknown. WA has been shown to exhibit angiogenesis inhibition through NF-κB inhibition and the ubiquitin-proteasome pathway was thought to be involved (Mohan et al., 2004) . However, the direct target molecule of WA involved in the multiple steps of the proteasome-ubiquitin system has never been identified.
Results of the present study, for the first time, show the β5 subunit of the proteasome is the primary target of WA, inhibition of which leads to prostate cancer cell apoptosis. More
importantly, our work also demonstrates that the tumor proteasomal chymotrypsin subunit is also an in vivo biological target of WA in human cancer, inhibition of which is associated with tumor growth inhibition. The present study also supports the usefulness of computational modeling for identifying natural proteasome inhibitors and understanding their molecular mechanisms of action.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. µmol/L Celastrol (Cel) or Dihydrocelastrol (Di Cel) for different hours, followed by Western blotting analysis using antibodies against AR, PARP and actin (E) and caspase-3 activity (F).
